Navigation Links
CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Date:10/18/2007

VIENNA, Va., Oct. 18 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) announced today that its Chief Executive Officer, Geert Kersten, is a featured presenter at the International Society for Pharmaceutical Engineering (ISPE) 2007 Chesapeake BioShowcase in Gaithersburg Maryland. Mr. Kersten will present on the "New Realities for Funding a Small Biotechnology Company" today at 3:15 p.m. (Eastern Daylight Time).

In April 2007, CEL-SCI completed a $15 million private placement of common stock and warrants at a premium to where its common stock was trading at the time. In addition, in August 2007, CEL-SCI entered into a novel $15 million financing transaction in which it acquired the 20 year use of a dedicated manufacturing facility for its Phase III cancer drug Multikine(R). CEL-SCI is in the strongest financial condition in the Company's history.

ISPE is the Society of choice for 25,000 pharmaceutical manufacturing professionals in 90 countries around the globe. ISPE aims to be the catalyst for "Engineering Pharmaceutical Innovation" by providing Members with opportunities to develop technical knowledge, exchange practical experience, and collaborate with global regulatory agencies and industry leaders.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  Mirabilis Medical, a ... for non-invasive surgery, announced today CE Mark authorization ... of uterine fibroids throughout the European Union.  The ... from the US Food and Drug Administration to ... in the United States.  The Mirabilis System combines ...
(Date:3/23/2017)... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. ... The Global Cryostat Market is ... next decade to reach approximately $3.5 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:3/23/2017)... 23, 2017  Transportation Insight, a multi-modal lead logistics ... chain management firm with expertise serving clients in the ... Rick Zaffarano was named a 2017 Food ... by the only publication exclusively dedicated to covering the ... "Rick has brought to Transportation Insight a ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... stories about real people of God in congregations across the United States. ... Presbyterian minister ordained in 1964 who has served congregations in seven states throughout ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The physicians ... location in the greater Houston Area. The new location is located at 2255 E. ... Hospital in Springwoods Village. This newest location will provide patients living in the north ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... ... clinic, located at 960 Gruene Road in Building 2. The clinic is the group’s ... Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things full ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
Breaking Medicine News(10 mins):